Abstract
INTRODUCTION
Early detection in gastric cancer is increasing with screening endoscopy. Consequently early gastric cancer (EGC) which was resectable with endoscopic resection has increased. In gastric cancer, the most significant factor in endoscopic resection is the absence of lymph node metastasis (LNM) because it determines the treatment. For that reason, prediction of lymph node metastasis in EGC is very important.
The predictors of the absence of LNM in EGC were tumor size of 2 cm or smaller, histologically differentiated type, intramucosal cancer, and no lymphovascular (LV) invasion [1] . According to the risk factors of LNM, endoscopic submucosal dissection (ESD) is a standard treatment for differentiatedtype adenocarcinoma without ulceration, of which the depth of invasion is up to muscularis mucosa and the diameter is below 2 cm (Japanese gastric cancer treatment guidelines 2010 [1] ). However, some recent studies have reported extended indications for endoscopic resection [2] [3] [4] [5] [6] in differentiated EGC without lymphatic or vascular involvement, including: (1) mucosal cancers with no ulcerative findings, regardless of tumor size; (2) mucosal cancers with ulcerative findings ≤ 30 mm; and (3) minute (≤ 500 μm from the muscularis mucosae) submucosal invasive cancers ≤ 30 mm.
However, evidence from these studies is limited in South Korea. Thus, the purpose of this study was to determine the risk factors of lymph node metastasis in EGC removed by gastrectomy and to determine the safety of extended criteria for endoscopic treatment of EGC in South Korea.
MATERIALS AND METHODS
A total of 2270 patients who had undergone gastrectomy with lymph node dissection for EGC at Yeungnam University hospital and Keimyung University hospital and we retrospectively reviewed the patient who has been taken radiologic imaging study and upper gastrofibroscope, and confirmed pathological reports after operation.
The patient profiles were investigated, including sex, age, tumor location, size, ulceration, histological type, lymphovascular invasion, and depth of invasion. Well and moderately differentiated tubular adenocarcinoma and papillary adenocarcinoma were classified as differentiated lesions. Poorly differentiated adenocarcinoma, signet ring cell carcinoma, and mucinous carcinoma were categorized as undifferentiated types. Lesions with ulcer or ulcer scar within cancer were regarded as ulcerated lesions. The depth of submucosal invasion was checked from the muscularis mucosa to the point of deepest penetration. The depth of submucosal invasion was subclassified according to two groups: SM1 (≤ 500 μm penetration into submucosa) and SM2 (> 500 μm). The tumor size was measured by the results of the pathological report after surgical resection.
Statistical analysis was performed using the SPSS program. The relationship between lymph node metastasis and various factors was assessed using the simple χ 2 test and multiple logistic regression analysis.
RESULTS

Baseline characteristics of enrolled patients and EGC
Male to female ratio was 1488:782 and mean age was 59.3 ± 11.7. The mean length of major axis was 25.9 ± 16.5 mm. The most common location of early gastric cancer was middle anterior wall of stomach. Table 1, Table 2 and Table  3 . Tumor size, lymphatic or venule invasion, deeper vertical invasion, and ulceration were the risk factors of lymp node metastasis. Similar to the finding for cancer involving intramucosa, significant correlation was observed between tumor larger than 3 cm and lymphovascular invasion with an increased risk of LNM. Also, cancer with involvement deep into the submucosa showed greater association with LNM; and significant correlation was observed between tumor larger than 2 cm and lymphovascular invasion and LNM in submucosal cancer. This meant that the possibility of LNM in cancer with involvement deep into the submucosa was greater than in smaller sized tumor than in intramucosal cancer.
Risk factors of LNM
Suggestion for expanded indication of endoscopic resection for EGC
According to extended criteria, 3 (0.8%, 3/378) differentiated intramucosal lesions without lymphovascular invasion and ulceration regardless of tumor size showed association with LNM. Two (0.9%, 2/230) differentiated intramucosal ulcerative lesions below 3 cm without lymphovascular invasion showed association with LNM. Three (2.7%, 3/113) differentiated submucosal (≤ 500 μm from the muscularis mucosae) lesions were below 3 cm without lymphovascular invasion (Table 4 ). Although there were few patients with LNM in cases reflected by extended criteria, the possibility of LNM in EGC remained.
In our study, none (0/102) of the differentiated intramucosal lesions below 1 cm without lymphovascular invasion and ulceration showed association with LNM. In particular, there was no lymph node metastasis (0/127) in cases of well differentiated early gastric cancer below 1 cm in size without ulcer regardless of lymphovascular invasion. The undifferentiated intramucosal cancer below 1 cm in size with ulcer did not show association with metastasis. One (1.2%, 1/81) of the undifferentiated early gastric cancers below 1 cm without ulcer regardless of lymphovascular invasion showed association with LNM. The cell type of the patient in one case was signet ring. Thus, there was no LNM in patients with early gastric cancer below 1 cm in the without ulcer group without signet ring type cancer in cell differentiation (Table 4) .
Relative contraindication of endoscopic resection for EGC
Of 406 patients with undifferentiated M cancer, 2.7% (11/406) were found to have LNM. Seven patients with perilymphatic-vascular invasion were confirmed LNM and four of them had no ulcerated lesion. In 11 patients with LNM, one case was below 10 mm in size (Table 4) . (Figure 1 ).
DISCUSSION
The definition of EGC was suggested by the Japanese Gastroenterologic Endoscopic Society in 1962. In this definition, EGC is defined as gastric cancer which invades within submucosa regardless of lymph node metastasis [7] . The existence of LNM was association with bad prognosis [8] . The 5-year survival rate is > 90% in EGC, and the absence of lymph node metastasis is the most significant prognostic factor [9, 10] . The 5-year survival rate was reported to be 87.3% in patients with regional lymph nodes metastasis and 94.2% in those without [11] . Maruyama et al [12] reported that the number of metastatic lymph nodes in patients with EGC was associated with the survival rate. EGC patients with LNM had a lower survival rate than patients without lymph node metastasis [13] . Because of an increased accuracy of diagnosis of EGC, which in turn leads to a better prognosis, increased interest has been focused on betterment of the quality of life and minimalization of invasive procedures. Furthermore, nowadays, various minimally invasive treatment modalities have been developed and endoscopic resection has enabled rapid restoration of patient's health with lower risk of procedure, however, this endoscopic treatment also has risk of disease recurrence and distant metastasis.
Therefore, we suggested investigation of the relationship between various risk factors and LNM, and we think that our research will be helpful in development of more delicate criteria for endoscopic resection of EGC.
The overall incidence of a LNM in EGC ranges from 10% to 15% [9, 10, 14, 15] . The incidence of lymph node invasion was reported upto 4.8% in mucosal cancers and 23.6% in SM cancers [9, 10, 16] . These results are similar to ours generally, and the incidence of LNM was similar to those in mucosal carcinoma reported by Yamao et al [17] and Tsujitani et al [18] , and lower risk in submucosal carcinoma reported by other researchers [19] . So far, standard treatment of SM cancer is gastrectomy with lymphadenectomy [20] . But, endoscopic resection such as EMR or ESD is widely used standard treatment modality for mucosal cancer [9, 21] . In studies analyzing the outcome of endoscopic resection in undifferentiated EGC, complete resection rate of undifferentiated EGC was relatively lower than that of differentiated EGC [22] . There were various attempts to clarify risk factors predicting LNM and relationship between these risk factors and prognosis. Maehara et al [23] found that large tumor, lymphatics involvement, and submucosal invasion were risk factors for LNM in EGC patients. Yamao et al [17] also reported that lymphatic invasion, histologic type, and large tumor size were independent risk factors for LNM in intramucosal EGC. In our study, univariate and multivariate analysis showed association of LNM in EGC with large tumor size, submucosal invasion, and perilymphatic-vascular invasion. Some researchers have advocated that submucosal invasion is the most predictive risk factor for LNM. Otherwise, of risk factors for metastasis, the most important is perilymphatic invasion [24] . As for lymphatic vascular invasion, this may be the most important direct route to the regional lymph nodes [6] . Relation of prognostic factors, including gender, tumor size, depth of invasion, endoscopic findings, and lymphatic invasion to LNM in SM cancer has been demonstrated [20, 25, 26] . Besides pathologic type, Lauren classification and perineural involvement also showed significant and independent association with LNM.
However, Keita Nakahara et al [6] reported that the histological type was not a risk factor for LNM. In our results, histological type and presence of differentiation were unrelated to LNM. And, in the study by Nakahara et al [6] , no significant difference in invasion depth was observed between SM1 and M cancers among EGC. Yet, in our studies, a statistically significant difference was observed between SM1 and M, and SM1 and SM2. With respect to size and ulceration, the possibility of SM invasion is higher and ulceration develops more readily in larger lesions. In contrast, there was no difference between ulcerated lesion and LNM in M, SM1, and SM2 (Table 1) . Molecular biologically, proliferating cell nuclear antigen labeling index of greater than 25%, matrix metalloproteinase-9-positive tumors, tumor with gastric mucin phenotype, and vascular endothelial growth factor-C-positive tumors showed an association with LNM [27] . EMR has been widely used for treatment of EGC. However, current application of EMR is limited to differentiated EGC [28] . Endoscopic resection is basically contraindicated even in differentiated type submucosal gastric cancer. In fact, Kunisaki et al [29] reported that the incidence of LNM was 1.8% in patients with submucosal gastric cancer measuring less than 20 mm and without lymphovascular invasion, and the site of LNM was restricted to the paragastric lymph nodes. Kurihara et al [19] reported that reoperation after an endoscopic resectio for EGC with SM1 invasion is unnecessary because most SM1 cancers < 20 mm do not have the lymph node metastasis. Gotoda et al [4] reported that none of 145 differentiated adenocarcinomas < 30 mm, a lack of lymphovascular invasion and submucosal penetration < 500 μm, had nodal metastasis [4] . Gotoda et al [4] proposed an extension of the indications for endoscopic treatment, and one of the extended indications was differentiated SM1 adenocarcinoma measuring less than 30 mm [4] . Abe et al [30] also reported that an EMR could be suitable for SM1 cancers and no lymphatic invasion. Abe et al [30] suggested that SM cancer with < 15 mm in diameter could be treated by EMR or a local resection. In our study, there were few patients with LNM in cases reflected by extended criteria. However, the possibility of LNM in EGC remained. In particular, there was no LNM in patients with EGC below 1 cm without ulcer in the group without signet ring type cancer in cell differentiation (Table 4) . Korenaga et al [31] reported that accurate assessment of depth of cancer invasion was difficult in lesions larger than 15 mm resected piecemeal.
Clinically, it is difficult to determine whether lesions are confined to the mucosa or not [32, 33] . Also, several studies reported that assessment of depth of cancer invasion after endoscpic resection is inaccurate in up to 20% of lesions [32, 33] . Biopsies are too superficial to provide this information, but EMR provides a larger specimen, which allows assessment of depth of cancer invasion and lymphovascular invasion [4] . But, when resection if fragmented, the bruised margin makes it difficult to evaluate the stump, and the degree of radical treatment cannot be adequately evaluated. This issue is particularly important in lesions for which local treatment is indicated. When en bloc/total resection is technically impossible, indications of EMR should not be readily extended [6] . In addition, accurate evaluation of the presence of lymphatic vascular invasion preoperatively or before endoscopic resection is impossible, therefore, postoperative histological evaluation is essential.
Endoscopic ultrasonography, computed tomography etc. were widely used by staging of EGC. But, resected tissue by EMR or ESD and radiological examination could not exclude perfectively regional LNM. However, recently, minimal invasive surgery or stomach conserving therapy such as sentinel node navigation surgery, hybrid NOTES, and endoscopic submucosal dissection with sentinel node navigation surgery has been newly developed [34, 35] . In addition, from the technical perspective of en block/total resection, a condition of 30 mm or less may be considered safe [6] . The new endoscopic technique or tools such as ESD and IT knife enable complete resection of large and ulcerated lesions.
Because of the high probability of LNM and tumor residual, patients with submucosal undifferentiated EGC are not candidates for treatment by EMR [28] . By our studies, 66 (20.3%) cases of 324 undifferentiated SM cancer were related to LNM.
In the Kunisaki et al [36] study, the incidence of LNM in patients with poorly differentiated type mucosal cancer was 2.2%. In this study, the incidence of LNM was 3.4% in patients with undifferentiated mucosal tumors. Therefore, endoscopic resection may be contraindicated in these patients.
As mentioned above, currently, exclusion of histologically poorly differentiated submucosal gastric cancer from the indications for endoscopic resection is mandatory, whereas histologically differentiated submucosal gastric cancer can be curatively resected endoscopically [36] . However, endoscopic resection may be reasonable for histologically undifferentiated mucosal gastric cancer below 10 mm in size and without lymphovascular invasion, for undifferentiated submucosal cancer less than 10 mm and without lymphovascular invasion in elderly patients with severe co-morbid disease, because the incidence of LNM is low in these patients.
In conclusion, we suggest that depth of tumor infiltration, tumor size as a maximum tumor diameter, and perilymphovascular invasion are independent risk factors for LNM in EGC.
Our study shows that there was no LNM in intramucosal cancer which was not signet ring cell type and was below 1 cm without ulceration regardless of lymphatic invasion. This means that ESD can be the treatment of choice in patients with intramucosal cancer below 1 cm without ulceration.
ESD has shown advantages over conventional EMR for removal of larger or ulcerated EGC lesions in an en bloc manner as well as for prevention of residual disease and local recurrence. Some reports showed LN metastasis in EGC of extended indication, particularly in submucosal invasive EGC. Our study shows LN metastasis in EGC of extended criteria, too. But, the possibility of LNM in intramucosal cancer of extended indication was below 1%. Many more cases of materials and more large scaled multicenter studies are essential for development of eligibility criteria for endoscopic treatment of EGC.
COMMENTS
Background
Recently endoscopic resection of early gastric cancer (EGC) has been widely performed. In endoscopic treatment, the presence of lymph node metastasis (LNM) is the most important issue. However, data on risk factors for LNM in South Korean EGC have been limited. The aims of this study were to find risk factors of LNM in EGC and to find proper endoscopic therapy indication in EGC.
Research frontiers
According to the risk factors of LNM, endoscopic submucosal dissection (ESD) is a standard treatment for differentiated-type adenocarcinoma without ulceration, of which the depth of invasion is up to muscularis mucosa and the diameter is below 2 cm. However, recent studies have reported extended indications for endoscopic resection in differentiated EGC with no lymphatic or vascular involvement, including: (1) mucosal cancers without ulcerative findings, regardless of tumor size; (2) mucosal cancers with ulcerative findings ≤ 30 mm; and (3) minute (≤ 500 μm from the muscularis mucosae) submucosal invasive cancers ≤ 30 mm. However, evidence from these studies is limited in South Korea.
Innovations and breakthroughs
Although the depth of tumor infiltration, tumor size as a maximum tumor diameter, and perilymphovascular invasion are independent risk factors for LNM in EGC, there was no LNM in intramucosal cancer which was not signet ring cell type and was below 1 cm without ulceration regardless of lymphatic invasion. This means that ESD can be the treatment of choice in patients with intramucosal cancer below 1 cm without ulceration. Gotoda et al proposed an extension of the indications for endoscopic treatment, and one of the extended indications was histologically differentiated type SM1 tumor measuring less than 30 mm. But, there was LN metastasis in EGC of extended criteria in this study. However, the possibility of LNM in intramucosal cancer of extended indication was below 1%.
Applications
There was no LNM in intramucosal cancer which was not signet ring cell type and was below 1 cm without ulceration regardless of lymphatic invasion. This means that ESD can be the treatment of choice in patients with intramucosal cancer below 1 cm without ulceration.
Terminology
The depth of submucosal invasion was subclassified according to two groups: SM1 (≤ 500 μm penetration into submucosa) and SM2 (> 500 μm). Extended indication criteria for endoscopic resection in differentiated EGC with no lymphatic or vascular involvement, includes: (1) mucosal cancers without ulcerative findings, regardless of tumor size; (2) mucosal cancers with ulcerative findings ≤ 30 mm; and (3) minute (≤ 500 μm from the muscularis mucosae) submucosal invasive cancers ≤ 30 mm.
